Madrigal Pharmaceuticals/$MDGL
1D1W1MYTD1Y5YMAX
Capital at risk
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
- Ticker
- $MDGL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 915
- Headquarters
- West Conshohocken, United States
- Website
- www.madrigalpharma.com
MDGL Metrics
BasicAdvanced
$12B
-
-$16.37
-0.99
-
Price and volume
Market cap
$12B
Beta
-0.99
52-week high
$615.00
52-week low
$393.61
Average daily volume
252K
Financial strength
Current ratio
3.205
Quick ratio
2.756
Long term debt to equity
0.662
Total debt to equity
0.664
Interest coverage (TTM)
-10.24%
Profitability
EBITDA (TTM)
-321.098
Gross margin (TTM)
91.48%
Net profit margin (TTM)
-25.32%
Operating margin (TTM)
-25.13%
Revenue per employee (TTM)
$1,400,000
Management effectiveness
Return on assets (TTM)
-17.84%
Return on equity (TTM)
-53.31%
Valuation
Price to revenue (TTM)
8.095
Price to book
23.07
Price to tangible book (TTM)
23.07
Price to free cash flow (TTM)
-49.661
Free cash flow yield (TTM)
-2.01%
Free cash flow per share (TTM)
-10.537
Growth
Revenue change (TTM)
149.04%
Earnings per share change (TTM)
10.93%
3-year earnings per share growth (CAGR)
-4.21%
10-year earnings per share growth (CAGR)
8.14%
What the Analysts think about MDGL
Analyst ratings (Buy, Hold, Sell) for Madrigal Pharmaceuticals stock.
Analyst projections of the future price of Madrigal Pharmaceuticals stock.
Bulls say / Bears say
Q2 2026 net sales of Rezdiffra reached $364.3 million, representing 71% year-over-year growth, highlighting robust launch momentum and strong market adoption. (GlobeNewswire)
As of June 30, 2026, active patients on Rezdiffra surpassed 49,000—a more than twofold increase from Q2 2025—and crossed 50,000 in early July, indicating accelerating physician uptake and patient demand. (GlobeNewswire)
Madrigal expanded its MASH pipeline in February 2026 by securing an exclusive global licensing agreement with Suzhou Ribo for six preclinical siRNA programs, with $60 million upfront and potential payments up to $4.4 billion, diversifying beyond its lead asset resmetirom. (Madrigal IR)
The company reported a Q2 2026 net loss of $57.9 million ($1.99 per share), compared to a $42.3 million loss in Q2 2025, underscoring continued unprofitability despite strong revenue growth. (GlobeNewswire)
Cash, cash equivalents, restricted cash, and marketable securities declined to $838.9 million as of June 30, 2026, down from $988.6 million at year-end 2025, reflecting significant cash burn to support operations and pipeline investments. (GlobeNewswire)
Operating expenses surged to $420.6 million in Q2 2026—driven by $91.2 million in R&D and $289.4 million in SG&A—more than offsetting revenue gains and pressuring near-term profitability. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2026.
MDGL Financial Performance
Revenues and expenses
MDGL Earnings Performance
Company profitability
Upcoming events
No upcoming events
MDGL News
AllArticlesVideos
Funds containing MDGL
AllUSDGBPEUR
Fund name | Fund size | $MDGL weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.83% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.83% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.14% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.14% |
iShares MSCI World Small Cap$WSML | $9B | 0.07% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.